Literature DB >> 16839724

Nonlinear properties of otoacoustic emissions in normal and impaired hearing.

A R D Thornton1, B Lineton, V J Baker, A Slaven.   

Abstract

Click-evoked otoacoustic emissions (CEOAEs) exhibit nonlinearities in amplitude and time domains. The first objective of this study was to investigate whether there is any correlation between the temporal and amplitude nonlinearities of CEOAEs in normals. Additionally there is evidence that pathology affects the normal cochlear nonlinearity. The second objective was to investigate whether pathology affects the temporal nonlinear components. Conventional and maximum length sequence (MLS) CEOAEs were recorded in normal subjects and in patients with mild hearing loss. The slope of the input-output (I/O) function of the conventional CEOAE measured the amplitude nonlinearity. Two measures of temporal nonlinearity were the magnitude of the suppression that occurs with increase in stimulus rate and the amplitudes of the second and third order temporal interaction components (Volterra slices). The amplitude nonlinearity is well correlated with both the magnitude of the rate suppression and the amplitudes of the Volterra slices. The 'linear' CEOAE amplitude showed no differences between the normal and patient groups but the differences in the Volterra slices were substantial. This suggests that the first sign of damage to the cochlea is that the system becomes more linear. Hence the Volterra slices may provide a sensitive measure of cochlear damage.

Entities:  

Mesh:

Year:  2006        PMID: 16839724     DOI: 10.1016/j.heares.2006.05.010

Source DB:  PubMed          Journal:  Hear Res        ISSN: 0378-5955            Impact factor:   3.208


  2 in total

1.  Linear and nonlinear temporal interaction components of mid-latency auditory evoked potentials obtained with maximum length sequence stimulation.

Authors:  Brigitte A Lavoie; Angela Barks; A R D Thornton
Journal:  Exp Brain Res       Date:  2009-12-05       Impact factor: 1.972

2.  COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.

Authors:  Simon J Crabb; Karen Martin; Julia Abab; Ian Ratcliffe; Roger Thornton; Ben Lineton; Mary Ellis; Ronald Moody; Louise Stanton; Angeliki Galanopoulou; Tom Maishman; Thomas Geldart; Mike Bayne; Joe Davies; Carolynn Lamb; Sanjay Popat; Johnathan K Joffe; Chris Nutting; John Chester; Andrew Hartley; Gareth Thomas; Christian Ottensmeier; Robert Huddart; Emma King
Journal:  Eur J Cancer       Date:  2017-11-10       Impact factor: 9.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.